Cargando…

Emerging Therapeutic Targets in Ovarian Cancer

Despite rapid advances in understanding the biology of ovarian cancer, progress in treatment has been slow. But the prospects for improvement have never been better. A wide range of novel therapeutic targets now present themselves for clinical evaluation and initial results are certainly encouraging...

Descripción completa

Detalles Bibliográficos
Clasificación:Libro Electrónico
Autor Corporativo: SpringerLink (Online service)
Otros Autores: Kaye, Stan (Editor ), Brown, Robert (Editor ), Gabra, Hani (Editor ), Gore, Martin (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: New York, NY : Springer New York : Imprint: Springer, 2011.
Edición:1st ed. 2011.
Temas:
Acceso en línea:Texto Completo

MARC

LEADER 00000nam a22000005i 4500
001 978-1-4419-7216-3
003 DE-He213
005 20220118152522.0
007 cr nn 008mamaa
008 101123s2011 xxu| s |||| 0|eng d
020 |a 9781441972163  |9 978-1-4419-7216-3 
024 7 |a 10.1007/978-1-4419-7216-3  |2 doi 
050 4 |a RC261-271 
072 7 |a MJCL  |2 bicssc 
072 7 |a MED062000  |2 bisacsh 
072 7 |a MJCL  |2 thema 
082 0 4 |a 571.978  |2 23 
082 0 4 |a 616.994  |2 23 
245 1 0 |a Emerging Therapeutic Targets in Ovarian Cancer  |h [electronic resource] /  |c edited by Stan Kaye, Robert Brown, Hani Gabra, Martin Gore. 
250 |a 1st ed. 2011. 
264 1 |a New York, NY :  |b Springer New York :  |b Imprint: Springer,  |c 2011. 
300 |a XIII, 291 p.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
520 |a Despite rapid advances in understanding the biology of ovarian cancer, progress in treatment has been slow. But the prospects for improvement have never been better. A wide range of novel therapeutic targets now present themselves for clinical evaluation and initial results are certainly encouraging. In this text, all these areas are covered by experts in the field. Each chapter provides up-to-date coverage of clinical information, prefaced by a description of the rational basis for the selection of each target area and consideration of biomarkers that can be used to aid clinical evaluation. The four editors work together within the Ovarian Cancer Action collaborative research programme in London and they bring a wealth of laboratory and clinical expertise to this topic. The text should provide an invaluable source of reference for clinical and laboratory-based researchers working to meet the challenges of ovarian cancer. 
650 0 |a Cancer. 
650 0 |a Pharmacology. 
650 1 4 |a Cancer Biology. 
650 2 4 |a Pharmacology. 
700 1 |a Kaye, Stan.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Brown, Robert.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Gabra, Hani.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Gore, Martin.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer Nature eBook 
776 0 8 |i Printed edition:  |z 9781441972156 
776 0 8 |i Printed edition:  |z 9781489982339 
776 0 8 |i Printed edition:  |z 9781441972170 
856 4 0 |u https://doi.uam.elogim.com/10.1007/978-1-4419-7216-3  |z Texto Completo 
912 |a ZDB-2-SBL 
912 |a ZDB-2-SXB 
950 |a Biomedical and Life Sciences (SpringerNature-11642) 
950 |a Biomedical and Life Sciences (R0) (SpringerNature-43708)